---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-003563"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2025-02-12T23:59:59+00:00"
generated_at: "2026-05-26T22:46:56.549081+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma reports Q2 net income $0.8M; Pediatric revenue up 86% sequentially

## Summary
- Net revenue $16.2M, down 13% YoY; ADHD revenue fell 17% to $13.8M, Pediatric rose 12% to $2.4M.
- Net income $0.8M ($0.13 basic EPS) vs net loss $0.2M in Q2FY24; adjusted EBITDA $1.3M vs $5.5M.
- Sequential prescription growth for both ADHD and Pediatric portfolios, first since Q2FY23.
- Cash $20.4M at Dec 31, 2024, flat vs Sep 30; cost savings initiatives to cut at least $2M annually.
- Gross margin 66% vs 78% a year ago due to higher-cost ADHD inventory from manufacturing transition.

## SEC filing metadata
- accession: 0001437749-25-003563
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2025-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/0001437749-25-003563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000143774925003563/aytu20241121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-003563
- JSON: https://secwatch.observer/filing/0001437749-25-003563.json
- Plain text: https://secwatch.observer/filing/0001437749-25-003563.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.